<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gater, Laura</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nauck, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">GLP-1 — The New Darling of Diabetes Treatment</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates postprandial insulin secretion. The incretin effect is believed to be critical for maintenance of normal plasma glucose and glucose tolerance [Diab 1995]. Experiments using antagonists of the GLP-1 receptor show that GLP-1 is responsible for a substantial part of the insulin response to oral glucose [Diab 1995; Diab 1994]. This article discusses GLP-1 receptor agonists and DPP IV inhibitors.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>